Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
5Customers
2Debt Items
11Related Chains
Source-Backed Evidence Depth
Oncolytics Biotech Inc. (ONCY) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
11Total relationships
3Distinct source URLs
6High confidence
0.793Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Oncolytics Biotech Inc. Suppliers
Ticker
Name
Confidence
Evidence
JEFFERIES-LLC
JEFFERIES-LLC
92%
the Company may offer and sell from time to time through or to the agent, acting as agent or principal, shares of the Company’s common stock
ALUMNI-CAPITAL-LP
ALUMNI-CAPITAL-LP
90%
On April 10, 2025, we entered into a standby equity purchase agreement (the “SEPA Arrangement”) with Alumni Capital LP ("Alumni"), as described further in Note 7 of the consolidated financial stateme…
Reciprocal relationship from GNLX graph: g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial.…
Oncolytics Biotech Inc. Customers
Ticker
Name
Confidence
Evidence
PANCREATIC-CANCER-ACTION-NETWORK
PANCREATIC-CANCER-ACTION-NETWORK
90%
concentration of credit risk consist primarily of cash and cash equivalents and other receivables from the Pancreatic Cancer Action Network
Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements w…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
sation, and other employee-related expenses. Intellectual property expenses include legal and filing fees associated with our patent portfolio. Office expenses include administrative costs associated…
CASH-RESOURCES
CASH-RESOURCES
62%
strointestinal Tumor Scientific Advisory Board Established In support of our mCRC and SCAC clinical programs, we formed our Gastrointestinal Tumor Scientific Advisory Board, a group of leading oncolo…
OPERATIONS-ONCOLYTICS-BIOTECH-INC
OPERATIONS-ONCOLYTICS-BIOTECH-INC
62%
undable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries…
Oncolytics Biotech Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ONCY-DEBT-20261
Warrants outstanding: 2.81
90%
xbrl warrant detail from xbrl 2026-03-31.
ONCY-DEBT
Debt stack $563,000
90%
Market cache reports total debt of $563,000.
Oncolytics Biotech Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Oncolytics Biotech Inc..
Oncolytics Biotech Inc. Ownership
Holder
Name
Confidence
Evidence
ONCY-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 60 tracked holders.
Oncolytics Biotech Inc. Extended Supply Chain Network
